Internet-based Intervention for Skin Self-Examination in Participants with Increased Risk for Melanoma
This trial studies an internet-based intervention for skin self-examination (SSE) in participants with increased risk for melanoma. Early detection of suspicious growths on the skin can be done by performing regular SSE checks. Using an internet-based intervention, such as mySmartCheck, may help to promote regular, thorough checks on the skin in participants with increased risk for melanoma.
- At increased risk for melanoma due to a personal history of treated melanoma without current evidence of disease, a family history of melanoma in a first-degree relative, and/or having a high-risk mole phenotype (i.e., >= 50 normal moles or >= 1 abnormal mole [dysplastic nevus]).
- Access to a computer connected to the Internet.
- Not adherent to SSE recommendations (i.e., did not conduct a thorough SSE during each of the previous 3 months).
- Able to speak and read English.
- Able to provide informed consent.
Locations & Contacts
Contact: Elliot J. Coups
Trial Objectives and Outline
I. To evaluate the impact of mySmartCheck on SSE behaviors among individuals at increased risk for developing melanoma.
I. To evaluate the impact of mySmartCheck versus usual care on patients’ barriers and benefits to conducting SSE, SSE self-efficacy (confidence), level of worry about developing melanoma, and number of health care consultations (visits, telephone calls, and emails).
II. To identify barriers and facilitators to using mySmartCheck.
PHASE I: Participants attend a telephone interview and participate in 2-5 user testing sessions of mySmartCheck program over 60 minutes each for acceptability, satisfaction, comprehension, and usability.
PHASE II: Participants are randomized to 1 of 2 groups.
GROUP I: Participants attend a telephone interview over 15-20 minutes, receive access to mySmartCheck program, and continue to receive standard of care.
GROUP II: Participants receive standard of care.
After completion of study, patients are followed up for 13 weeks.
Trial Phase & Type
No phase specified
Rutgers Cancer Institute of New Jersey
Elliot J. Coups
Secondary IDs NCI-2018-02006, Pro20170000597
Clinicaltrials.gov ID NCT03725449